Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2028

Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
DRUG

Lenacapavir Injection

Administered subcutaneously

DRUG

Lenacapavir Tablet

Administered orally

DRUG

Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

Administered orally

Trial Locations (14)

6202

CHU Nice Archet, Nice

13006

Hopital Europeen Marseille, Marseille

75010

Hopital Saint Louis - Assistance Publique des Hopitaux de Paris, Paris

75012

APHP Hopital Saint-Antoine, Paris

75018

APHP Bichat Claude-Bernard Hospital, Paris

93000

Hopital Avicenne, Bobigny

B9 5SS

University Hospitals Birmingham NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham

BN2 3EW

Clinical Research Facility, University Hospitals Sussex NHS Foundation Trust, Brighton

L7 8YE

Axess Sexual Health, Liverpool University Hospitals NHS Trust, Liverpool

E11BB

Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, Barts Health NHS Trust, London

E9 6SR

Homerton Healthcare NHS Foundation Trust, Homerton University Hospital, London

SE5 9RS

Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust, London

SW10 9NH

Chelsea and Westminster Hospital NHS Foundation Trust, Clinical Research Facility, Chelsea and Westminster Hospital, London

M13 0FH

Manchester University NS Foundation Trust, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY